10) Multiple Sclerosis Flashcards
What is the class for IFN-beta-1a (Avonex)
IFN-beta-1a
What is the mechanism for IFN-beta-1a (Avonex)
Many, potentially: inhibit T-cell activation, shift from Th1 to Th2, inhibit lymphocyte movement into CNS, anti-proliferative effect, apoptosis of T-cells, anti-viral, IFN-g antagonism
What are the therapeutics for IFN-beta-1a (Avonex)
RRMS
What are the important side effects for IFN-beta-1a (Avonex)
Mild anemia, increase LFT (monitor every 6 mo.), hypothyroid; least NAB formed
What are the other side effects for IFN-beta-1a (Avonex)
Flu-like, minor irritation at inject site, anemia
What are the miscellaneous for IFN-beta-1a (Avonex)
Doesn’t cross BBB; decreases relapse rate by 1/3 and reduces MRI lesions, with a trend toward decreasing disability and brain atrophy
What is the class for IFN-beta-1a (Rebif)
IFN-beta
What is the mechanism for IFN-beta-1a (Rebif)
Many, potentially: inhibit T-cell activation, shift from Th1 to Th2, inhibit lymphocyte movement into CNS, anti-proliferative effect, apoptosis of T-cells, anti-viral, IFN-g antagonism
What are the therapeutics for IFN-beta-1a (Rebif)
RRMS (high-dose); first-line treatment (more efficacious than Avonex in head-to-head trials)
What are the important side effects for IFN-beta-1a (Rebif)
Anemia, leukopenia, menstrual irregularities, depression, increase LFT and hypothyroidism (monitor every 3 mo.)
What are the other side effects for IFN-beta-1a (Rebif)
Flu-like, injection site reaction; neutropenia; thrombocytopenia
What are the miscellaneous for IFN-beta-1a (Rebif)
As with Avonex; significantly reduces new and enhancing MRI lesions, reduces disablity
What is the class for IFN-beta-1b (Betaseron)
IFN-beta
What is the mechanism for IFN-beta-1b (Betaseron)
Many, potentially: inhibit T-cell activation, shift from Th1 to Th2, inhibit lymphocyte movement into CNS, anti-proliferative effect, apoptosis of T-cells, anti-viral, IFN-g antagonism
What are the therapeutics for IFN-beta-1b (Betaseron)
RRMS (high-dose); more efficacious than Avonex in head-to-head trials
What are the important side effects for IFN-beta-1b (Betaseron)
Leukopenia, menstrual irregularities, depression, increase LFT and hypothyroidism (monitor every 3 mo.); more NAB formed than avonex
What are the other side effects for IFN-beta-1b (Betaseron)
Flu-like, inject site reaction, anemia
What are the miscellaneous for IFN-beta-1b (Betaseron)
As with Avonex, but no effect on disease progression
What is the class for IFN-beta-1b (Extavia)
IFN-beta
What is the mechanism for IFN-beta-1b (Extavia)
Many, potentially: inhibit T-cell activation, shift from Th1 to Th2, inhibit lymphocyte movement into CNS, anti-proliferative effect, apoptosis of T-cells, anti-viral, IFN-g antagonism
What are the therapeutics for IFN-beta-1b (Extavia)
RRMS (high-dose)
What are the important side effects for IFN-beta-1b (Extavia)
Leukopenia, menstrual irregularities, depression, increase LFT and hypothyroidism (monitor every 3 mo.)
What are the other side effects for IFN-beta-1b (Extavia)
Flu-like, inject site reaction, anemia
What are the miscellaneous for IFN-beta-1b (Extavia)
As with Avonex, but no effect on disease progression
What is the class for Glatiramer acetate (Copaxone)
Myelin basic protein analog
What is the mechanism for Glatiramer acetate (Copaxone)
Mixture of 4 AAs in myelin basic protein; causes T-cell apoptosis (looks like MBP), induces anti-inflammatory Th2 cells (cytokine shift from Th1), induces Treg with induction of anergy
What are the therapeutics for Glatiramer acetate (Copaxone)
RRMS
What are the important side effects for Glatiramer acetate (Copaxone)
Mild: injection site reaction, anxiety attack-like reaction
What are the miscellaneous for Glatiramer acetate (Copaxone)
Active in CNS (not peripherally); try to use early; reduce relapse by 1/3, modest reduction in MRI lesion and reduction of atrophy, but no effect on disease progression
What is the class for Natalizumab (Tysabri)
Monoclonal antibody
What is the mechanism for Natalizumab (Tysabri)
Binds VLA4 (integrin subunit), inhibiting leukocyte migration across BBB
What are the therapeutics for Natalizumab (Tysabri)
RRMS (2nd line)